Loading stock data…
Biogen Inc. (BIIB)
$216.63+0.60 (+0.28%)
Market ClosedLast close Jun 29
Biogen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biogen Inc. in the Healthcare sector is trading at $216.63 with a market capitalization of $28.9B. Wall Street consensus targets $220.28 (31 analysts), implying a +1.7% move over the next 12 months. The stock is currently near its 52-week high of $219.72, remaining 22.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.48B↑ | $2.28B↓ | $2.53B↓ | $2.65B↑ | $2.43B |
| Gross Profit | $1.82B↑ | $1.78B↓ | $1.86B↓ | $2.04B↑ | $1.80B |
| Operating Income | $459.80M↑ | $385.50M↓ | $606.50M↓ | $851.80M↑ | $625.20M |
| Net Income | $319.50M↑ | -$48.90M↓ | $466.50M↓ | $634.80M↑ | $240.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.05
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.36%
Volume
Today's trading volume
1.19M
Recent News
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.
Why Biogen (BIIB) Stock Is Up Today
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth signals, including the $1 billion purchase of RayThera Inc., an FDA Breakthrough Therapy tag for its drug candidate Salanersen, and a recent analyst upgrade.
Lilly, J&J and AbbVie Hit New Highs
Lilly, AbbVie and J&J extend winning streaks.